HeartSciences Receives FDA Clearance for Enhanced AI Algorithm Suite

The expanded clearance includes new algorithms for cardiac triage and screening, bringing our total to 12 validated conditions.

HeartSciences continues to advance AI-enabled cardiovascular triage and screening with technology that enables earlier detection of cardiac conditions. Our mission is to help healthcare providers identify and treat heart disease earlier, ultimately improving patient outcomes across the healthcare continuum.

Background

Cardiovascular disease remains the leading cause of death globally, affecting millions of people each year. Traditional screening methods often miss early signs of cardiac dysfunction, leading to delayed treatment and worse outcomes for patients.

HeartSciences was founded to address this critical gap in cardiovascular care. By leveraging advanced artificial intelligence and machine learning technologies, we have developed algorithms capable of detecting subtle patterns in ECG signals that are invisible to traditional interpretation methods.

Clinical Validation

Our technology has been rigorously validated through multi-center clinical studies involving tens of thousands of patients. These studies, published in leading peer-reviewed journals, demonstrate the accuracy and reliability of our AI algorithms across diverse patient populations and clinical settings.

Looking Forward

HeartSciences remains committed to advancing the science of AI-enabled cardiovascular screening. We continue to invest in research and development, expanding our algorithm portfolio and improving screening accuracy across additional cardiac conditions.

For more information about HeartSciences and our technology, please visit our products page or contact our team to schedule a demonstration.